What you should know:
1. Todos is developing TM-C1, a blood-based diagnostic test for colon cancer.
2. Todos is in the midst of studying TM-C1.
3. When elaborating on the next steps for TM-C1, Dr. Weiss referenced Exact Sciences’ developmental path.
“Exact Sciences has shown successful adoption for their colon cancer stool test and we believe we can replicate their roadmap to success with a simple blood test,” Dr. Weiss said.
4. The company has blood-based tests for breast and other cancers in development.
More articles on gastroenterology::
Pennsylvania’s $12.5M tax on ASCs could cause dozens to close, lawmaker says — 5 key points
Novant Health makes $1.8B impact with network of outpatient facilities, medical centers
Vermont Gov. signs ASC licensure bill into law — 5 key details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.